Prediction of therapeutic efficacy of infliximab for refractory ulcerative colitis by analyzing and measuring serum concentration of cytokines and infliximab

Prediction of therapeutic efficacy of infliximab for refractory ulcerative colitis by analyzing and measuring serum concentration of cytokines and infliximab - Prediction of therapeutic efficacy of IFX for refractory UC by measuring serum cytokines and IFX

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010205

Enrollment

100

Registered

2013-03-10

Start date

2013-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory ulcerative colitis who are candidates for infliximab therapy.

Exclusion criteria

Exclusion criteria: Patients who refuse the induction infliximab therapy or those who don't agree with participating in this study after sufficient written explanation.

Design outcomes

Primary

Measure	Time frame
The correlation between the clinical and endoscopic efficacy of infliximab for ulcerative colitis and the serum concentration of IL-6, TNF-alpha and IFX.	—

Countries

Japan

Contacts

Public ContactTadakazu Hisamatsu

School of Medicine, Keio University Division Gastroenterology and Hepatology, Department of Internal Medicine

hisamachi@a7.keio.jp03-5363-3790

Outcome results